In five trials [15–17, 19], patients had a mix of primary, de novo and secondary AML, with FLT3 inhibitors given as part of induction and/or consolidation treatment in three trials [16, 17] plus maintenance up to 12 months in two [15, 19]. The gene discussed is FLT3; the disease is acute myeloid leukemia.